English (UK)
中文版- 1
- 2
Absenteeism. Presenteeism. 
Virtual meetings Host, Guest, Panelist, Master of Ceremonies.
Mr. Leo Petrilli
Addiction Recovery Coach AND MentorBioPegasus, LLC 
BioPegasus, LLC specializes in a cost-effective and robust post-proteomics and post-protein and peptide array technology biomarker and target discovery technology platform. This proprietary platform is unique and transformative, allowing systematic, thorough and unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time. It aims to accelerate novel therapeutic and diagnostic development for some devastating diseases to improve our health and quality of life. These diseases include autoimmune diseases, cancer, and, in particular, Alzheimer’s disease.
BioPegasus' technology platform provides a revolutionary tool for systematical and thorough studying novel molecular interactions and mechanism of actions with any molecule of interest. The platform can be used to provide contract services with royalty payment potential to research institutions and companies in IVD, biotech and pharma sectors. The technology can also be packaged into commercial product(s) with a user manual for sale in the market world-wide.
BioPegasus currently is operated by its founder looking for an investor(s), partner(s), and sponsor(s)/client(s) or any form of collaboration/interest.
Dr. Tianlin Ma
FounderDyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company focused on improving and applying its proprietary C1 gene expression platform, based on a patented and proprietary genetically modified strain of the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), to address opportunities in the human and animal health markets. C1 is a potentially game-changing biopharmaceutical gene expression platform that may help bring biologic vaccines, drugs and other biologic products to market faster and more efficiently than existing expression platforms, such as Chinese hamster ovary (CHO) cells, E. coli, yeast and baculovirus in greater volumes, at lower cost and with new properties that can improve access and cost to patients and the healthcare system.
Ping Rawson
CFOEnzymogen 
Enzymogen is a biotechnology company developing cannabinoids in algae as new drug entities.
Main activities:
Development of a platform for producing API cannabinoids based on proprietary technology (not plant extracts);
Develop cannabinoids as drugs for unmet clinical needs.
Mr. Meir Azulay
Director
Ferro Pharma 
One of our brand, EMELEMA® - Making Latest Medicine Available – is what we believe in and what drives the best talent from around the globe to join us.
Our aim is to be known as the company that increases patient access to generic and innovative medicine. We focus on building bridges between markets, stakeholders and patients. Collectively, we believe in finding the most fair, straight and reliable provider for the distribution of Active Pharmaceutical Ingredients (API), Finished Dosage Forms (FDF) and services. Thanks to our dedicated teams in Brazil, China, Germany, India and Malta, we are using manufacturing plants for high quality products, in the most efficient way. We direct our attention on novel delivery systems and the provision of EU registered and manufactured drugs..
We made quality our priority. The EMA, FDA and ANVISA standards for APIs and FDFs are our benchmarks that we fulfill.
We operate worldwide but our core markets are China, Latin America and the European Union.
Responsive Web Design powered by 